Publication:
Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden

dc.contributor.authorGonzález-Moreno, Juan
dc.contributor.authorGaya-Barroso, Aina
dc.contributor.authorLosada-López, Inés
dc.contributor.authorRodríguez, Adrián
dc.contributor.authorBosch-Rovira, Teresa
dc.contributor.authorRipoll-Vera, Tomas
dc.contributor.authorUson, Mercedes
dc.contributor.authorFiguerola, Antoni
dc.contributor.authorDescals, Cristina
dc.contributor.authorMontala, Carles
dc.contributor.authorFerrer-Nadal, Maria Asunción
dc.contributor.authorCisneros-Barroso, Eugenia
dc.date.accessioned2024-09-18T06:42:03Z
dc.date.available2024-09-18T06:42:03Z
dc.date.issued2021-06-10
dc.description.abstractBackground: Hereditary transthyretin (TTR) amyloidosis (ATTRv) is a heterogeneous disease with a clinical presentation that varies according to geographical area and TTR mutation. The symptoms of Val50Met-ATTRv are mainly neuropathic and progress to complete disability and death in most untreated patients within 10 to 15 years of diagnosis. The neurological effects may also be accompanied by gastrointestinal impairment, cardiomyopathy, nephropathy and/or ocular deposition. The disease is thus associated with a high degree of patient disability. Accordingly, we aimed to describe the psychosocial burden associated with ATTRv in a group of patients, asymptomatic Val50Met carriers, relatives and caregivers in the endemic focus of the disease in Majorca via a survey addressing various aspects related to psychosocial burden. We performed a an observational, descriptive, cross-sectional and multicentre study in order to analyze the prevalence of self-reported impact of ATTRv disease upon their daily life. In addition to the self-knowledge, fear and burden related to the disease. The survey was disseminated during the regular follow up at the outpatient clinic of the Hospital Universitario Son Llatzer and during the meetings organized by the andrade's Disease patients' advocacy group from the Balearic Islands. These meetings were attended also by subjects followed up by the Hospital Universitario Son Espases and their caregivers and relatives. Survey was self-administrated. No intervention was done by the investigators. 85 subjects completed the survey: 61 carrying the TTR-V50M variant and 24 caregivers or relatives. Results: Our study revealed that, although most of the population studied had had prior contact with ATTRv through affected relatives, there was still a lack of information regarding disease diagnosis. Fear of the genetic test result and psychological issues were common in our population. Moreover, the disease had a stronger impact on the daily life of our patients than that of our asymptomatic carriers. Autonomic symptoms were the main source of burden for relatives and caregivers. Conclusion: Our survey results show high psychosocial burden associated with Val50Met-ATTRv in our area.en
dc.description.sponsorshipThis work was sponsored by Alnylam Pharmaceuticals. The authors had full editorial control over the results presented here and the interpretation of the findings.es_ES
dc.format.number1es_ES
dc.format.page266es_ES
dc.format.volume16es_ES
dc.identifier.citationGonzalez-Moreno J, Gaya-Barroso A, Losada-Lopez I, Rodriguez A, Bosch-Rovira T, Ripoll-Vera T, et al. Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden. Orphanet J Rare Dis. 2021 Jun 10;16(1):266.en
dc.identifier.doi10.1186/s13023-021-01910-5
dc.identifier.e-issn1750-1172es_ES
dc.identifier.journalOrphanet Journal of Rare Diseaseses_ES
dc.identifier.otherhttps://hdl.handle.net/20.500.13003/19900
dc.identifier.pubmedID34112225es_ES
dc.identifier.puiL2012332014
dc.identifier.scopus2-s2.0-85107461469
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23154
dc.identifier.wos664111600004
dc.language.isoengen
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://dx.doi.org/10.1186/s13023-021-01910-5en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHereditary transthyretin amyloidosis
dc.subjectBurden of disease
dc.subjectRare disease
dc.subjectWell-being
dc.subjectCaregivers
dc.subject.decsEstudios Transversales*
dc.subject.decsNeuropatías Amiloides Familiares*
dc.subject.decsPrealbúmina*
dc.subject.decsHumanos*
dc.subject.decsEspaña*
dc.subject.meshPrealbumin*
dc.subject.meshSpain*
dc.subject.meshHumans*
dc.subject.meshAmyloid Neuropathies, Familial*
dc.subject.meshCross-Sectional Studies*
dc.titleVal50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burdenen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files